Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $57.7 million versus the consensus estimate of $58.18 million.

GUIDANCE:

Corcept Therapeutics sees Q2 2018 revenue of $275-300 million, versus the consensus of $290.2 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.